Expertise in
12
conditions

Dr. Tara C. Mitchell

Hematology | Oncology
Perelman Center For Advanced Medicine Oncology
3400 Civic Center Blvd, Fl 4, 
Philadelphia, PA 
Accepting New Patients
Offers Telehealth
Referral may be required
Expertise in
12
conditions
Perelman Center For Advanced Medicine Oncology
3400 Civic Center Blvd, Fl 4, 
Philadelphia, PA 

Overview

Tara Mitchell is a Hematologist and an Oncologist practicing medicine in Philadelphia, Pennsylvania.

Dr. Mitchell is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Melanoma, Merkel Cell Carcinoma, Teratocarcinosarcoma, and Olfactory Neuroblastoma.

Dr. Mitchell is board certified in Medical Oncology, 2010. She is actively involved in clinical research, co-authoring 83 peer reviewed articles and participating in 4 clinical trials. Dr. Mitchell is currently accepting new patients.

Graduate Institution

New York University School Of Medicine

Residency

Indiana University Hospital

Specialties

Hematology
Oncology

Licenses

Internal Medicine in PA

Board Certifications

Medical Oncology, 2010

Fellowships

University of Chicago Medical Center

Hospital Affiliations

Hospital Of Univ Of Pennsylvania
Chester County Hospital
Pennsylvania Hospital
Penn Presbyterian Medical Center
University Medical Center Of Princeton At Plainsboro

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Avalon Health Care
  • MEDICARE PDP
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Geisinger
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Provider Partners Health Plan
  • MEDICARE SNP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Perelman Center For Advanced Medicine Oncology
3400 Civic Center Blvd, Fl 4, Philadelphia, PA 19104
Other Locations
Abramson Cancer Center Perelman 3rd Floor West
3400 Civic Center Boulevard, West Pavilion, 3rd Floor, Philadelphia, PA 19104

Additional Areas of Focus

Dr. Mitchell has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Melanoma
Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma
A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma
Enrollment Status: Completed
Publish Date: August 25, 2026
Intervention Type: Biological, Radiation
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Randomized Phase 2 Trial of Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma
A Randomized Phase 2 Trial of Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 17, 2026
Intervention Type: Drug, Radiation
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
A Phase 1a/1b Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies
A Phase 1a/1b Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: October 09, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
Enrollment Status: Completed
Publish Date: April 19, 2022
Intervention Type: Drug, Biological
Study Drugs: GEN-009 Adjuvant Vaccine, Nivolumab, Pembrolizumab
Study Phase: Phase 1/Phase 2
View 3 Less Clinical Trials

83 Total Publications

Immune checkpoint blockade in desmoplastic melanoma.
Immune checkpoint blockade in desmoplastic melanoma.
Journal: Nature cancer
Published: February 06, 2026
Similar Doctors
Expertise in
12
conditions
Dr. Janet L. Kwiatkowski
Hematology | Oncology
Expertise in
12
conditions
Dr. Janet L. Kwiatkowski
Hematology | Oncology
Referral may be required

Office

3401 Civic Center Blvd, 
Philadelphia, PA 
 (0.1 miles away)
215-590-1000
Languages Spoken:
English
See accepted insurances

Janet Kwiatkowski is a Hematologist and an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Kwiatkowski is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Hemolytic Anemia, Congenital Hemolytic Anemia, Anemia, Bone Marrow Transplant, and Splenectomy.

Expertise in
13
conditions
Dr. John M. Maris
Hematology | Oncology
Expertise in
13
conditions
Dr. John M. Maris
Hematology | Oncology
Referral may be required

Office

3500 Civic Center Blvd, 
Philadelphia, PA 
 (0.1 miles away)
215-590-3025
Languages Spoken:
English

John Maris is a Hematologist and an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Maris is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Gliomatosis Cerebri, and Rhabdomyosarcoma.

Expertise in
17
conditions
Dr. Stephan A. Grupp
Hematology | Oncology
Expertise in
17
conditions
Dr. Stephan A. Grupp
Hematology | Oncology
Referral may be required

Office

3401 Civic Center Blvd, 
Philadelphia, PA 
 (0.1 miles away)
215-590-1000
Languages Spoken:
English
See accepted insurances

Stephan Grupp is a Hematologist and an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Grupp is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Hepatic Venoocclusive Disease with Immunodeficiency, Acute Lymphoblastic Leukemia (ALL), Leukemia, Adult T-Cell Leukemia, and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Tara C. Mitchell

How do I make an appointment with Dr. Tara C. Mitchell?

You can book an appointment with Dr. Tara C. Mitchell by calling their office at 215-615-5858. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Tara C. Mitchell a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Tara C. Mitchell is classified as an Elite expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Tara C. Mitchell specialize in?

While Dr. Tara C. Mitchell is a Hematology, they have specific expertise in Melanoma, Merkel Cell Carcinoma, and Teratocarcinosarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Tara C. Mitchell participate in research or clinical trials?

Yes. Dr. Tara C. Mitchell has published 83 articles and abstracts on conditions like Melanoma. You can view a list of Dr. Tara C. Mitchell's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Tara C. Mitchell accept my insurance?

Dr. Tara C. Mitchell accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 215-615-5858 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mitchell's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 35 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile